The tweet was deleted by the author.
But we saved everything 🙂.
Michael Taylor, co-founder and portfolio manager at Agora Trading, highlights a new partnership between Summit Therapeutics and AstraZeneca for developing new standards of care in lung and other cancers.
The companies have entered a $2 billion preferred convertible deal, with meaningful data expected in squamous lung cancer in the fourth quarter.
View post on X Loading...
Taylor previously flagged AQRT’s Phase 2 vitiligo study set for the fourth quarter of 2026, targeting a $1 billion market and aiming to double total addressable market size, as detailed in recent coverage. In an earlier note, he identified FJET as a little-known bear trade opportunity, urging investors to review relevant developments in that report. These calls reflect Taylor’s ongoing focus on emerging clinical milestones and unique trade ideas.